Neuren Pharmaceuticals stock | Price, analyst rating, price target & growth

Neuren Pharmaceutica...

ASX:NEU

$ 12,23

$-0,29 (-2,32%)

12,23 $

$-0,29 (-2,32%)

End-of-day quote: 04/13/2026

Neuren Pharmaceuticals Stock Value

Analysts currently give ASX:NEU a rating of Buy.

Buy

Neuren Pharmaceuticals Company Info

EPS Growth 5Y

64,13%

Market Cap

$1,59 B

Long-Term Debt

$0,00 B

Quarterly earnings

05/30/2026 (E)

Dividend

$0,00

Dividend Yield

0,00%

Founded

2001

Industry

Health Care

Country

Australia

Website

Neuren Pharmaceuticals

ISIN Number

NZNEUE0001S8

Website

http://www.neurenpharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$23,18

89.53%

Last Update: 04/13/2026

Analysts: 6

Highest Price Target $29,00

Average Price Target $23,18

Lowest Price Target $18,40

In the last five quarters, Neuren Pharmaceuticals’s Price Target has fallen from $28,25 to $24,97 - a -11,61% decrease. Five analysts predict that Neuren Pharmaceuticals’s share price will increase in the coming year, reaching $23,18. This would represent an increase of 89,53%.

Top growth stocks in the health care sector (5Y.)

What does Neuren Pharmaceuticals do?

Neuren Pharmaceuticals Limited is a publicly listed biopharmaceutical company developing drugs for neurological disorders. The company's primary focus is on developing innovative therapies that address significant unmet medical needs in the field of neurodevelopmental disorders. Business Segments The company operates within two primary business segments including Commercial Products and Research & Development. Commercial Products This segment generates milestone and royalty revenue through l...

Business Segments

The company operates within two primary business segments including Commercial Products and Research & Development.

Commercial Products

This segment generates milestone and royalty revenue through licensing agreements related to its intellectual property. The company's commercial relationships with pharmaceutical companies, particularly Acadia Pharmaceuticals Inc., are crucial for securing ongoing revenue streams and validating its discoveries in the marketplace.

Research & Development

This segment is focused on the exploration and development of novel pharmaceutical products aimed at treating neurodevelopmental conditions. It involves intensive activities such as preclinical and clinical trials to establish the safety and efficacy of new drug candidates, all while adhering to strict regulatory standards and protocols.

Business Strategy

The company’s business strategy revolves around leveraging its intellectual property portfolio, forming strategic partnerships, and focusing on its core competencies in drug development specific to neurological disorders. The company aims to bring innovative treatments to market while ensuring that the development aligns with robust scientific and clinical validation.

At the heart of this strategy is an emphasis on collaboration with established pharmaceutical entities to enhance the likelihood of successful commercialization. Moreover, the company is dedicated to maintaining a robust research and development pipeline that emphasizes the advancement of its current candidates while exploring new targets that can address significant healthcare needs.

The operational effectiveness is bolstered through ongoing monitoring of scientific advancements and market trends, ensuring the company remains agile and responsive to the evolving landscape of neurological treatments. The commitment to R&D and the strategic focus on collaborative partnerships project a sustainable growth trajectory for the company, positioning it favourably within the industry.

Products and Services

The company focuses primarily on pharmaceutical products designed to treat neurodevelopmental disorders. This specialization includes the development of innovative and effective therapies which are rigorously tested through extensive preclinical and clinical trials. The pipeline emphasizes the depth of research that goes into each potential product to ensure that the therapies not only meet regulatory standards but also have the potential to make a meaningful difference in patient care.

The company has entered into licensing agreements to expand its commercial reach. These agreements stipulate various forms of payments, including upfront fees, milestone payments contingent upon certain achievements in product development, and royalties based on future sales.

Geographical Markets Served

The company primarily operates in the North American market, with significant licensing activities centred around the United States. The revenue derived from licensing agreements, particularly from Acadia Pharmaceuticals, indicates a strong presence in this critical geographical landscape.

Customers

The company primarily serves the biopharmaceutical sector through its licensing agreements, focusing on partnerships with established pharmaceutical companies. The key customer in the licensing arrangements includes Acadia Pharmaceuticals Inc., which holds rights to the company’s intellectual property for commercialization in the U.S. market.

Marketing/Distribution Channels

The company employs a licensing model as its primary mode of sales and marketing. This approach allows for efficient market penetration without the need to establish a direct sales force. Instead, the focus lies in collaborating with larger pharmaceutical companies that can leverage their distribution channels and marketing expertise to bring the company’s innovations to healthcare professionals and patients effectively.

Regulations

Compliance with regulatory standards, particularly regarding drug development and marketing, is critical for the successful launch and commercialization of pharmaceutical products. The company engages with regulatory bodies, including the U.S. Food and Drug Administration, to ensure that all products meet legal standards and undergo necessary evaluations before reaching the market.

History

Neuren Pharmaceuticals Limited was incorporated in 2001.

Neuren Pharmaceuticals Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by industry:** - Biopharmaceuticals: 100% (2026) **TOP 3 markets and their percentage shares:** - USA: 60% - Europe: 25% - Asia-Pacific: 15% Neuren Pharmaceuticals Limited generates all its revenues from the biopharmaceutical industry, with a strong focus on developing thera...

At which locations are the company’s products manufactured?

**Production Location:** United States (2026) Neuren Pharmaceuticals Limited mainly produces its products in the United States. The company specializes in developing therapies for neurological disorders and collaborates closely with production partners in the USA to ensure the manufacturing and dis...

What strategy does Neuren Pharmaceuticals pursue for future growth?

**Focus on Clinical Trials:** Continuation and Expansion (2026) **Partnerships:** Expansion of Strategic Alliances (2026) **Product Pipeline:** Diversification and Innovation (2026) Neuren Pharmaceuticals Limited is pursuing a growth strategy that heavily focuses on advancing its clinical trials....

Which raw materials are imported and from which countries?

**Raw Materials/Ingredients:** Pharmaceutical active ingredients, excipients **Main Import Countries:** USA, Europe, China Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of therapies for neurological disorders. The main raw materials imported by th...

How strong is the company’s competitive advantage?

**Market share:** Estimated at 5-10% in the niche area of neurological therapies (2026). **Research and Development (R&D) expenses:** 20 million AUD (2025). **Patent portfolio:** Over 50 active patents (as of 2026). Neuren Pharmaceuticals Limited has established a solid competitive advantage...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 45% (estimated, 2026) **Insider Buys/Sells:** No significant transactions in the last quarter (2026) The institutional investor share in Neuren Pharmaceuticals Limited is estimated to be around 45%. This indicates a strong interest from institutional investors, r...

What percentage market share does Neuren Pharmaceuticals have?

**Market share of Neuren Pharmaceuticals Limited (ASX:NEU):** Estimate: 5% (2026) **Top competitors and their market shares:** 1. **Biogen Inc.:** 20% 2. **Roche Holding AG:** 18% 3. **Eli Lilly and Company:** 15% 4. **Novartis AG:** 12% 5. **Pfizer Inc.:** 10% 6. **Neuren Pharmaceuticals Limited:*...

Is Neuren Pharmaceuticals stock currently a good investment?

**Revenue growth:** 18% (2025) **Research and development expenses:** 25% of revenue (2025) **Market approvals:** Two new drugs in the last two years In recent years, Neuren Pharmaceuticals Limited has experienced strong revenue growth of 18%, attributed to successful market approvals and increased...

Does Neuren Pharmaceuticals pay a dividend – and how reliable is the payout?

**Dividend payment:** No dividend (2026) Neuren Pharmaceuticals Limited has not paid any dividends in the past and continues this trend in 2026. The company focuses on research and development in the field of neuroscience, which typically requires high investments. As Neuren Pharmaceuticals is in...

New support ticket

Explore

Neuren Pharmaceuticals Stock Value

Neuren Pharmaceuticals Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Neuren Pharmaceuticals do?

Neuren Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Neuren Pharmaceuticals Stock Value

Neuren Pharmaceuticals Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Neuren Pharmaceuticals do?

Neuren Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.